GT Biopharma, Inc.
8000 Marina Blvd, Suite 100
Brisbane, CA 94005
October 18, 2022
Via EDGAR Submission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jimmy McNamara
|Re:||GT Biopharma, Inc.|
|Registration Statement on Form S-3|
|Filed on October 13, 2022|
|File No. 333-267870|
Dear Mr. McNamara:
Pursuant to Rules 460 and 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), GT Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”) be accelerated so that it will become effective at 5:00 p.m., Eastern Time, on Thursday, October 20, 2022, or as soon as practicable thereafter. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Baker & McKenzie LLP, by calling Roger W. Bivans at (214) 978-3095.
Thank you for your assistance with this matter.
|Very Truly Yours,|
|By:||/s/ Manu Ohri|
|Title:||Chief Financial Officer|
cc: Roger W. Bivans, Baker & McKenzie LLP